The leaping development of biopharmaceutical industry

biopharmaceutical industry is a strategic emerging industry with the national key development, which is in line with Beijing's strategic orientation The municipal committee and the municipal government attach great importance to it and put forward the overall requirement of "crossing the development" In April 2010, the Municipal Science and Technology Commission launched and implemented the "Beijing Biopharmaceutical Industry Leapfrog Development Project" (i.e., the "G20 Project"), in accordance with the "government guidance, market selection, focus on enterprises, scale development" work ideas, set up an efficient co-ordination mechanism, led by the city director, the Municipal Science and Technology Commission, The Central Committee of The City, the Municipal Investment Promotion Bureau set up a G20 working group to jointly promote the development of biopharmaceutical industry from the new industry to the industrial industry In October 2012, the second phase of the G20 project was launched, and in April 2014, the municipal government issued the Beijing Technology Innovation Action Plan (2014-2017), implementing 12 major projects such as the leapfrog development of the biopharmaceutical industry These measures will further give full play to the resources, technology and market advantages of Beijing's biopharmaceutical field, accelerate the transformation and upgrading of Beijing's biopharmaceutical industry to a "high-precision" industry, and make it an important support and representative area of the national science and technology innovation center, and serve the capital's innovation and development First, the biopharmaceutical industry is to strengthen the Beijing national science and technology innovation center core function of the key grasp (1) in line with Beijing's development and positioning of biomedicine industry is the country and Beijing's key development of strategic emerging industries, with knowledge-intensive, high value-added, high radiation, low energy consumption and low pollution and so on Since the 11th Five-Year Plan, the biopharmaceutical industry has become the representative of Beijing's emerging high-tech industry and the leading force of the national pharmaceutical industry through measures such as industry policy guidance, industrial environment construction and financial support The total factor productivity of Beijing's biopharmaceutical industry increased from 9% in 2003-2007 to 22.7% in 2008-2012, and the growth mode was gradually transformed from "capital-driven" to "technology-driven" In 2012, the efficiency of technology transformation ranked first among the six high-tech manufacturing industries in the city, and the value added of Beijing's biopharmaceutical industry increased by 13.92 percent year-on-year, ranking second in the city's manufacturing industry, second only to the automobile manufacturing industry In 2013, the annual operating income of all enterprises in the pharmaceutical manufacturing industry was RMB86.03 billion, up 13.6% YoY, which was higher than the city's industrial growth rate of 6.9 percentage points (2) The advantages of resource elements highlight beijing's concentration of Tsinghua University, Peking University, the Chinese Academy of Medical Sciences, the Academy of Military Medical Sciences and other 72 relevant institutions As of 2012, Beijing has 40% of the country's national key laboratories, 20% of the national engineering centers, 20% of the national drug safety evaluation center and 16% of the international clinical research base; "12th Five-Year Plan" so far, Beijing has received the national "major new drug creation" special funds of more than 2.2 billion yuan, accounting for about 27% of the country, ranking first in the country From 2010 to 2012, Beijing obtained 295 clinical approvals of new drugs, accounting for 18.23% of the country, ranking first in the country (3) With regard to the industrial elements with a solid industrial base, the implementation of the G20 project has doubled the industrial scale in two years, to 100 billion yuan in three years and to 117.63 billion yuan in 2013 The total number of single varieties of more than 500 million yuan reached 23, including The first locally cultivated 1 billion yuan variety in Beijing, "Kaishi" Attract 6 pharmaceutical multinational companies to set up a global research and development center in Beijing The pharmaceutical industry park represented by Zhongguancun Life Science Park in the north and Daxing Biopharmaceutical Industry Base in the south has a reasonable layout and perfect function, and the income accounts for more than 80% of the pharmaceutical industry in the city, with a significant concentration effect In terms of policy mechanism, the head of the municipal government led the decision-making of the various commissions and bureaus to make collective decisions on major matters, jointly implement the promotion, the government funds to achieve the whole chain coverage, key stage of centralized support layout model, strengthen the use of financial funds scientific, effective, bidding procurement, medical insurance catalog and other key industry policies have made breakthroughs, to a certain extent from the market side to promote innovation Second, the innovation-driven effect is obvious lying that the government guides the innovation input 4 years to strive for major national special funds of more than 1.2 billion yuan, city co-ordination funds of more than 1 billion yuan, to promote more than 230 varieties into clinical research, 54 varieties to obtain new drug certificates and production approvals In 2013, the Beijing region received the "12th Five-Year Plan for major new drug creation" and the city's science and technology program projects totaled more than 860 million yuan, driving a total investment of 2.14 billion yuan On the one hand, through the transformation of large varieties, so that Beijing more than 1 billion yuan of large varieties up to 8, 500 million yuan or more varieties up to 23, accounting for 25.6% of the city's pharmaceutical manufacturing scale; Excellent varieties to obtain clinical approval, Yuekang pharmaceutical industry "Lafurtin capsules" and other 12 innovative excellent varieties to obtain production approval, guide and promote Baiji Shenzhou and Germany Merck Sherano and other 30 achievements in Beijing, for the follow-up development reserves a number of innovative varieties G20 engineering has become an important player in attracting high-end talent Four years to attract 36 international high-end talent team to Beijing development, nearly 40 billion funds to invest in Beijing In 2013, 11 international-level high-end talent teams, such as Liu Hongyu protein drug design and bioactivity evaluation team, were introduced to Beijing for development, 9 of which landed in Beijing; "Haiju Project Plan", up to now a total of 85 biopharmaceutical enterprises selected, from the G20, ABO enterprises have 37 people, Shen Yuelei and other 3 imported talents to obtain the 10th batch of "thousand-person plan" entrepreneurial talent project, up to now, Beijing has 42 entrepreneurs in the field of biomedicine selected, including 23 from G20, ABO enterprises, strong support for the innovative development of enterprises The active introduction of innovative "incremental" results are significant In 2013, the total amount of investment in Beijing was 10.73 billion yuan, of which 5 projects of more than 500 million yuan, the cumulative investment amount of 4 years exceeded 40 billion yuan, 24 multinational pharmaceutical companies in Beijing to establish headquarters, research and development centers or high-end manufacturing bases The innovative "incremental" initiative has contributed more than 70% to the industry in terms of research and development investment, new product sales revenue and overall scale, and has made a significant contribution to promoting the adjustment of the "high-precision" industrial structure Third, the innovation environment is improving the whole industry chain of science and technology financial services system Municipal Science and Technology Commission, the People's Bank of China Business Management Department, the Municipal Banking Regulatory Bureau, the Municipal Financial Work Bureau continue to deepen the pilot financial incentive program, increase support for small micro-enterprises, in 2013 11 pilot commercial banks for 94 enterprises to provide a total of 217 loans, a total amount of 3.65 billion, of which 78 small and medium-sized enterprises, loans reached 940 million yuan, an increase of 7.7% year-on-year In four years, the financial science and technology funds 75 million, to guide 17 commercial financial institutions for 193 Beijing biomedical enterprises to issue a cumulative loan of 15.936 billion, more than 200 times the amplification effect With the support of the National Development and Reform Commission and the Municipal Development and Reform Commission, the establishment of China's first professional fund focusing on the transformation of biomedical achievements - "Chongde Hongxin Achievement Transformation Fund", with a total scale of 263 million yuan; The public technical service platform strongly supports industrial innovation Strengthen the interaction of medicine, organize the Beijing Clinical Pharmacology Base to set up a "Clinical CRO Alliance", increase clinical trial research support for innovative pharmaceutical varieties in Beijing, mobilize the resources of more than 40 clinical institutions in Beijing, serve more than 1000 innovative varieties of Beijing biopharmaceutical enterprises in 4 years, and serve Beijing Biomedicine in 2013 Enterprises 434 projects, a total of 65.93 million yuan, respectively, increased by 29.6% and 15.7% over 2012, of which the total amount of G20 enterprises reached 45.14 million yuan, an increase of 36.5% over 2012 China Biotechnology Innovation Services Alliance (ABO) revenue exceeded 2 billion yuan, up 11% YoY, of which international service revenue exceeded 900 million yuan, 7 consecutive years of sales revenue and international orders growth.